Top Page
Eden Innovations
(Sydney:EDE)
Eden Innovations (EDE) vs. iShares MSCI Australia ETF (EWA)
Eden Innovations Business Overview & Revenue Model
Eden Innovations Financial Statement Overview
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.69M | 2.43M | 2.02M | 4.70M | 4.15M | 3.28M |
| Gross Profit | -696.84K | 1.68M | 1.39M | -2.17M | -3.36M | -3.10M |
| EBITDA | -2.84M | -3.93M | -4.83M | -15.08M | -4.49M | -3.73M |
| Net Income | -330.41K | -6.93M | -7.55M | -17.87M | -6.65M | -5.76M |
Balance Sheet | ||||||
| Total Assets | 17.99M | 17.84M | 19.07M | 17.00M | 25.79M | 24.48M |
| Cash, Cash Equivalents and Short-Term Investments | 3.66M | 561.18K | 975.20K | 2.53M | 1.55M | 2.18M |
| Total Debt | 3.89M | 16.34M | 12.79M | 10.21M | 4.91M | 5.26M |
| Total Liabilities | 6.63M | 19.59M | 15.10M | 12.28M | 6.30M | 6.34M |
| Stockholders Equity | 11.36M | -1.75M | 3.98M | 4.73M | 19.49M | 18.14M |
Cash Flow | ||||||
| Free Cash Flow | -3.18M | -3.70M | -5.27M | -5.11M | -7.51M | -7.46M |
| Operating Cash Flow | -3.18M | -3.70M | -5.22M | -4.17M | -6.03M | -5.55M |
| Investing Cash Flow | 6.34M | -305.20K | -586.79K | -940.93K | -1.48M | -1.91M |
| Financing Cash Flow | 1.01M | 3.59M | 4.26M | 6.09M | 6.78M | 8.45M |
Eden Innovations Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | AU$43.04M | 4.98 | 20.77% | 4.55% | 66.80% | 625.00% | |
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
57 Neutral | AU$15.80M | 3.85 | 13.83% | ― | -6.52% | -20.79% | |
50 Neutral | AU$45.57M | 13.58 | -15.10% | ― | 12.74% | -392.59% | |
43 Neutral | AU$66.52M | 10.16 | -6.88% | ― | 20.65% | 15.54% | |
42 Neutral | AU$37.86M | -7.05 | -38.77% | ― | ― | 15.66% |
Eden Innovations Corporate Events
Eden Innovations has amended a previous filing with the ASX to correct the number of new shares being quoted following the exercise of options or conversion of other securities. The updated Appendix 2A, dated 19 March 2026, revises the figure from 341,780 to 341,850 shares, slightly increasing the stated issued capital and providing an accurate reflection of the company’s current share base for investors and market participants.
The most recent analyst rating on (AU:EDE) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Eden Innovations stock, see the AU:EDE Stock Forecast page.
Eden Innovations Ltd has applied to the ASX for quotation of 1,036,007 new ordinary fully paid shares, with an issue date of 17 March 2026. The securities result from the exercise or conversion of existing options or other convertible instruments, modestly expanding the company’s quoted share capital and slightly diluting existing holders while raising no disclosed new capital.
The application formalizes the admission of these additional shares to trading under the existing EDE ticker on the ASX. While limited in scale, the move reflects ongoing use of equity-linked incentives or financing structures and incrementally increases the company’s free float and liquidity profile in the market.
The most recent analyst rating on (AU:EDE) stock is a Hold with a A$0.15 price target. To see the full list of analyst forecasts on Eden Innovations stock, see the AU:EDE Stock Forecast page.
Eden Innovations reported strong growth in U.S. OptiBlend sales, with revenue from the dual fuel kits exceeding US$1.18 million in the first 8.5 months of FY2026, more than 65% above the total OptiBlend revenue for all of FY2025. Since early February, the company has also quoted for 10 additional kits worth about US$559,000, including US$300,000 for data centres, underscoring rising demand for converting diesel generators to dual fuel operation.
The OptiBlend system replaces roughly 60%–70% of diesel with methane, lowering fuel costs and emissions while extending stored diesel runtime by up to 150% or more, which can significantly lengthen back-up power availability for critical facilities. With North American data centre investment projected to surge on the back of AI and cloud computing, Eden is positioning OptiBlend as a compelling solution to enhance resilience and sustainability of back-up power infrastructure in a rapidly expanding market.
The most recent analyst rating on (AU:EDE) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Eden Innovations stock, see the AU:EDE Stock Forecast page.
Eden Innovations has issued 2,507,505 fully paid ordinary shares following the exercise of an equivalent number of options priced at $0.07 each, including 607,428 shares allocated to a sophisticated investor under a shortfall offer linked to a previous entitlement offer. The company has confirmed that these shortfall shares were issued without a prospectus under relevant Corporations Act provisions and that it remains compliant with its financial reporting and continuous disclosure obligations, signalling routine capital management rather than a change in operational outlook.
The cleansing notice assures the market that there is no undisclosed material information relating to the newly issued shortfall shares, thereby facilitating secondary trading of these securities without additional disclosure. For investors and stakeholders, the move marginally increases Eden’s share capital while reaffirming regulatory compliance, supporting liquidity and reinforcing transparency around its capital-raising activities.
The most recent analyst rating on (AU:EDE) stock is a Hold with a A$0.15 price target. To see the full list of analyst forecasts on Eden Innovations stock, see the AU:EDE Stock Forecast page.
Eden Innovations has applied for quotation on the ASX of 2,507,505 new ordinary fully paid shares, with an issue date of March 2, 2026. The move modestly expands the company’s quoted share capital, potentially affecting liquidity and ownership structure, and reflects ongoing capital management activities that may support future operational or strategic initiatives.
The application confirms the securities will trade under the existing EDE ticker, maintaining continuity for investors and market tracking. While the announcement provides no detail on the reason for the new shares or the use of any associated funds, the additional quotation underscores Eden Innovations’ continued engagement with public equity markets as a funding and growth platform.
The most recent analyst rating on (AU:EDE) stock is a Hold with a A$0.15 price target. To see the full list of analyst forecasts on Eden Innovations stock, see the AU:EDE Stock Forecast page.
Eden Innovations reported a 14% decline in revenue to A$1.15 million for the half year to 31 December 2025, reflecting lower contributions from Optiblend kit sales in the U.S. and India. However, the company’s net result swung to a A$963,000 profit from a A$2.92 million loss, driven primarily by A$4.45 million in other income from the sale of a property in Georgia and reduced financing and administrative expenses.
Loss from ordinary activities narrowed by A$383,000 despite the revenue dip, indicating ongoing cost-cutting efforts across the group. Net tangible assets per share more than doubled to A$0.0206 following a 20-for-1 share consolidation, strengthening the balance sheet on a per-share basis, although auditors highlighted a material uncertainty related to going concern, underscoring continued financial and funding risks for shareholders.
The most recent analyst rating on (AU:EDE) stock is a Sell with a A$0.15 price target. To see the full list of analyst forecasts on Eden Innovations stock, see the AU:EDE Stock Forecast page.
Eden Innovations has decided to invest in new research and development equipment to expand the application of its carbon nanotube-enriched concrete technology to address the specialised needs of rapidly growing AI and cloud data centres. The company aims to optimise EdenCrete mixes to enhance heat dissipation and radio-frequency and electromagnetic shielding, tackling key infrastructure challenges such as thermal load management and EMP protection in these facilities.
The initiative builds on Eden’s transition to a debt-free status, a strengthened balance sheet and record demand for its concrete additives, as well as its success in commercialising low-cost, large-scale CNT production and patented dispersion technology. With CNT-enhanced concrete already approved by more than 20 U.S. Departments of Transportation and widely proven in infrastructure over 11 years, Eden is positioning itself to capture a share of the fast-growing global data centre construction market, projected to exceed USD 1 trillion by 2035.
The most recent analyst rating on (AU:EDE) stock is a Sell with a A$0.16 price target. To see the full list of analyst forecasts on Eden Innovations stock, see the AU:EDE Stock Forecast page.
Eden Innovations reported accelerating demand in the U.S. for its OptiBlend dual fuel kits, particularly from data centres using diesel generators for backup power. Since September 2025, the company has sold or received firm orders for nine OptiBlend kits to U.S. data centres worth about US$468,000, an amount that alone equals 79% of all U.S. OptiBlend sales recorded in the previous financial year.
Across all U.S. markets, OptiBlend sales and firm orders in the first eight months of FY2026 reached roughly US$743,000, already running 25% ahead of total FY2025 sales. Eden highlighted a strong pipeline, with live quotations over the past 20 months totaling about US$4.24 million, and argued that surging North American data centre investment and the operational benefits of OptiBlend position the product for sustained growth in the coming years.
The most recent analyst rating on (AU:EDE) stock is a Sell with a A$0.24 price target. To see the full list of analyst forecasts on Eden Innovations stock, see the AU:EDE Stock Forecast page.
Eden Innovations Ltd has notified the market of the issue of a new class of unquoted convertible notes, with a total of 2,200,000 securities to be issued on 9 February 2026. The notes form part of a previously announced transaction, are not quoted and are not intended to be quoted on the ASX, indicating a capital-raising or financing step that will not immediately affect the company’s listed share structure.
The move underscores Eden Innovations’ use of structured, unquoted instruments to secure funding or meet prior commitments while limiting direct dilution in its publicly traded securities. Investors and creditors will need to assess the terms and implications of these convertible notes over time, as any future conversion could alter the company’s capital base and ownership profile.
The most recent analyst rating on (AU:EDE) stock is a Sell with a A$0.14 price target. To see the full list of analyst forecasts on Eden Innovations stock, see the AU:EDE Stock Forecast page.
Eden Innovations has applied to the ASX for quotation of a new class of 20,000,000 options under the code EDEAU, each exercisable at A$0.07 and expiring on 8 September 2027. The listing of these options expands the company’s tradable securities and may provide additional capital-raising flexibility and liquidity for investors as part of its broader funding strategy.
The most recent analyst rating on (AU:EDE) stock is a Sell with a A$0.14 price target. To see the full list of analyst forecasts on Eden Innovations stock, see the AU:EDE Stock Forecast page.
Eden Innovations has lodged an application with the ASX for quotation of a new class of options, exercisable at $0.07 and expiring on 8 September 2027. The 1,000 options, issued as cleansing options to facilitate secondary trading and quotation of an existing Eden option series, are intended to support liquidity and orderly trading in the company’s derivative securities, potentially enhancing market accessibility for investors.
The move underscores Eden’s use of structured capital market instruments to manage its listed options and maintain compliance with exchange requirements. By enabling smoother secondary trading of its options, the company may improve price discovery and investor participation in its securities, though the small size of the issue suggests a largely technical or administrative adjustment rather than a material capital raise.
The most recent analyst rating on (AU:EDE) stock is a Sell with a A$0.14 price target. To see the full list of analyst forecasts on Eden Innovations stock, see the AU:EDE Stock Forecast page.
Eden Innovations has applied to the ASX for quotation of 131,177,806 options previously issued under an option cleansing prospectus, with the options exercisable at $0.07 and expiring on 8 September 2027. The options are spread across several issue dates between September and December 2025, and their quotation will formalize trading of these securities on the market, potentially enhancing liquidity and providing additional capital-raising flexibility for the company and investment opportunities for shareholders.
The application covers multiple new classes of options, each awaiting final ASX security codes, reflecting the company’s ongoing use of option-based instruments in its funding structure. By moving these options to quoted status, Eden Innovations aligns with ASX listing requirements and increases transparency for stakeholders regarding its capital structure and the terms of these derivative securities.
The most recent analyst rating on (AU:EDE) stock is a Sell with a A$0.14 price target. To see the full list of analyst forecasts on Eden Innovations stock, see the AU:EDE Stock Forecast page.
Eden Innovations has appointed longtime executive and chief scientist Dr Allan Godsk Larsen as managing director to lead its next phase of global expansion, leveraging his deep expertise in carbon material chemistry and his role in developing the EdenCrete product range. The move comes as the company reports record demand for its concrete admixtures, growing OptiBlend dual-fuel sales, and a significantly strengthened balance sheet, positioning it to scale internationally and pursue new infrastructure and energy opportunities.
EdenCrete Pz7 is gaining momentum with its largest order to date from Holcim Ecuador and growing usage in major U.S. projects, while Indian government testing has been expanded for potential highway and bridge applications. In parallel, OptiBlend sales are rising in the U.S. with new prospects in Africa and the Middle East, and Eden has cut about A$16 million in debt and removed high-interest quarterly obligations, improving cash flow and financial flexibility to support its growth strategy.
The most recent analyst rating on (AU:EDE) stock is a Sell with a A$0.14 price target. To see the full list of analyst forecasts on Eden Innovations stock, see the AU:EDE Stock Forecast page.
Eden Innovations Ltd has applied for ASX quotation of options previously issued to shareholders and investors who participated in its entitlement and entitlement shortfall offers, with the options exercisable at $0.07 each and expiring on 8 September 2027. The company has also released a Top 20 holder and distribution report for these quoted options, revealing a concentrated register led by Douglas and Gregory Solomon and several institutional and private investment vehicles, highlighting the ownership structure and potential influence of key stakeholders over the company’s future capital developments.
The most recent analyst rating on (AU:EDE) stock is a Sell with a A$0.12 price target. To see the full list of analyst forecasts on Eden Innovations stock, see the AU:EDE Stock Forecast page.
The company issued 341,780 fully paid ordinary shares after the exercise of options, including 100,001 shortfall shares taken up by a sophisticated investor under last year’s entitlement offer. Eden Innovations affirmed full compliance with its Corporations Act reporting obligations and confirmed no undisclosed information, reinforcing transparency for shareholders following the capital issuance.
The most recent analyst rating on (AU:EDE) stock is a Sell with a A$0.12 price target. To see the full list of analyst forecasts on Eden Innovations stock, see the AU:EDE Stock Forecast page.
Eden Innovations has lodged an Appendix 3B outlining plans to issue 1,000 options exercisable at A$0.07 and expiring on 8 September 2027, signalling a modest capital-raising move that could bolster liquidity and fund near-term development initiatives; the limited size of the option issue suggests the company is pursuing targeted financing rather than large-scale dilution, providing incremental flexibility for upcoming operational needs.
The most recent analyst rating on (AU:EDE) stock is a Sell with a A$0.12 price target. To see the full list of analyst forecasts on Eden Innovations stock, see the AU:EDE Stock Forecast page.
Eden Innovations Ltd has released an options cleansing prospectus for an offer of 1,000 Cleansing Options at no issue price, primarily to remove trading restrictions on existing options of the same class on issue before the closing date of 6 February 2026. The transaction-specific prospectus, prepared under section 713 of the Corporations Act, is designed to enable quotation of these Cleansing Options on the ASX and facilitate freer secondary trading, while emphasising that the securities are speculative and do not come with investment advice, thereby signalling a compliance-focused step that supports liquidity and regulatory clarity for current and prospective option holders.
The most recent analyst rating on (AU:EDE) stock is a Sell with a A$0.12 price target. To see the full list of analyst forecasts on Eden Innovations stock, see the AU:EDE Stock Forecast page.
Eden Innovations Ltd has applied to the ASX for quotation of 341,780 new ordinary fully paid shares, to be listed under its existing ticker EDE. The additional securities, issued on 4 February 2026 following the exercise or conversion of existing options or other convertible instruments, modestly expand the company’s quoted share capital and may provide incremental funding flexibility and liquidity for shareholders without materially altering its overall capital structure.
The most recent analyst rating on (AU:EDE) stock is a Sell with a A$0.12 price target. To see the full list of analyst forecasts on Eden Innovations stock, see the AU:EDE Stock Forecast page.
Eden Innovations has completed a major recapitalisation and debt refinancing, raising A$4.35 million through a placement and cutting total debt by about A$16 million via loan repayments, refinancing of high-interest borrowings, and conversion of shareholder loans, materially strengthening its balance sheet and financial flexibility. Operationally, the quarter saw growing commercial traction for its EdenCrete Pz7 admixture, including Holcim Ecuador’s largest order to date taking cumulative purchases above A$1 million and ongoing US projects, as well as promising Indian highway trials that could unlock a significant infrastructure market, while OptiBlend orders in the US—particularly from data centres—accelerated sharply, with recent order intake already approaching last year’s full OptiBlend sales and a substantial pipeline of quotations and purchase orders underpinning near-term revenue visibility.
The most recent analyst rating on (AU:EDE) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Eden Innovations stock, see the AU:EDE Stock Forecast page.
Eden Innovations has begun larger-scale trials of its EdenCrete Pz7 concrete admixture in India in collaboration with the government’s Central Road Research Institute, targeting two widely used concrete grades (M60 and M40 PQC) employed in major infrastructure works. The testing aims to enhance flexural strength and abrasion resistance in concrete used for bridge overlays, ultra-thin white topping and new pavements, potentially helping address India’s recent issues with premature highway pavement failures and aligning with the government’s shift toward higher-quality, more sustainable construction methods; if successful, the trials could significantly boost Eden’s Indian sales and open a sizeable market, including anticipated projects by the Maharashtra State Infrastructure Development Corporation.
The most recent analyst rating on (AU:EDE) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Eden Innovations stock, see the AU:EDE Stock Forecast page.
Eden Innovations Ltd has lodged details of a proposed capital raising with the ASX, outlining plans to issue up to 2.2 million convertible notes and 20 million options exercisable at A$0.07 and expiring on 8 September 2027. The proposed placement, scheduled for issue on 13 January 2026, is expected to strengthen the company’s funding position and provide additional financial flexibility, with potential dilution for existing shareholders but also offering scope to support future growth initiatives and operational needs.
The most recent analyst rating on (AU:EDE) stock is a Hold with a A$0.05 price target. To see the full list of analyst forecasts on Eden Innovations stock, see the AU:EDE Stock Forecast page.
Eden Innovations has secured a $2.2 million strategic convertible note from 7 Enterprises Pty Ltd to eliminate its remaining $2.7 million iBorrow loan, removing a high‑cost debt facility that was costing more than $1 million annually in interest and servicing. By fully repaying the iBorrow facility and replacing it with capitalised‑interest funding secured over a US property, Eden materially strengthens its balance sheet, reduces near‑term refinancing and cash flow risk, and improves the translation of its accelerating revenue growth—particularly in the US, OptiBlend quotations, and EdenCrete sales in Ecuador—into free cash flow, leaving the company better positioned for 2026 with institutional investor backing.
The most recent analyst rating on (AU:EDE) stock is a Hold with a A$0.05 price target. To see the full list of analyst forecasts on Eden Innovations stock, see the AU:EDE Stock Forecast page.
Eden Innovations has disclosed a change in the interests of director Doug Solomon, detailing adjustments to his direct and indirect holdings in the company’s shares and options. The change stems from a partial repayment of an outstanding loan through the issue of 28,571,428 fully paid ordinary shares and 14,285,714 unlisted options at a deemed price of A$0.035 per share, following shareholder approval on 18 December 2025, resulting in a substantial increase in Solomon’s indirect equity and option position and further aligning his interests with those of shareholders.
The most recent analyst rating on (AU:EDE) stock is a Hold with a A$0.05 price target. To see the full list of analyst forecasts on Eden Innovations stock, see the AU:EDE Stock Forecast page.
Eden Innovations has disclosed a significant change in the holdings of director Gregory Howard Solomon, following a shareholder-approved transaction that partially repaid an outstanding loan via the issue of new equity. Solomon, through his direct and indirect interests including Arkenstone Pty Ltd entities, acquired 28,571,428 fully paid ordinary shares and 14,285,714 unlisted options (exercisable at $0.07, expiring 8 September 2027) at a deemed price of $0.035 per share, increasing his indirect shareholding to 101,759,990 shares and unlisted options at $0.07 to 18,285,714. The transaction strengthens Eden Innovations’ balance sheet by reducing debt while further consolidating Solomon’s position as a key shareholder, underlining a strong alignment between the director’s interests and those of other investors.
The most recent analyst rating on (AU:EDE) stock is a Hold with a A$0.05 price target. To see the full list of analyst forecasts on Eden Innovations stock, see the AU:EDE Stock Forecast page.